Department of Reproductive Endocrinology & Infertility, National Institute for Research in Reproductive Health, Indian Council of Medical Research, J. M. Street, Parel, Mumbai 400 012, India.
Hum Reprod. 2012 Feb;27(2):408-17. doi: 10.1093/humrep/der410. Epub 2011 Dec 8.
Non-invasive diagnosis of endometriosis is urgently required to prevent the long delay between the onset of symptoms and diagnosis. A biomarker that possesses both high sensitivity and specificity is greatly required. Here, we describe the use of a proteomic approach to identify potential novel endometrial antigens using sera from endometriosis patients and healthy controls, with evaluation of biomarkers for non-invasive diagnosis of endometriosis.
A cross-sectional study was conducted to identify specific endometrial antigens using 1D and 2D western blots in women with early endometriosis (n = 17), advanced endometriosis (n = 23) and without endometriosis (n = 30). Five immunoreactive spots were analyzed using matrix-assisted laser desorption/ionization-time-of-flight/mass spectrometry with MASCOT analysis. ELISAs were established for specific epitopes and autoantibody titres were estimated in an independent cohort comprising women with early endometriosis (n = 18), advanced endometriosis (n = 32) and without endometriosis (n = 27) for validation.
The 2D western blot analysis resulted in the identification of three endometrial antigens, tropomyosin 3 (TPM3), stomatin-like protein 2 (SLP2) and tropomodulin 3 (TMOD3). Serum levels of antibodies against the epitopes from the immunodominant region of proteins TPM3, SLP2 and TMOD3 were significantly elevated in endometriosis patients when compared with controls. Sensitivity and specificity of serum anti-TPM3a-autoAb (61%, 93%), anti-TPM3c-autoAb (44%, 93%), anti-TPM3d-autoAb (78%, 89%), anti-SLP2a-autoAb (50%, 96%), anti-SLP2c-autoAb (61%, 93%), anti-TMOD3b-autoAb (61%, 96%), serum anti-TMOD3c-autoAb (78%, 93%) and anti-TMOD3d-autoAb (78%, 96%) were better than those of serum CA125 levels (21%, 89%) in the detection of early stages of endometriosis.
Serum anti-TPM3a-autoAb, anti-TPM3c-autoAb, anti-TPM3d-autoAb, anti-SLP2a-autoAb, anti-SLP2c-autoAb, anti-TMOD3b-autoAb, anti-TMOD3c-autoAb and anti-TMOD3d-autoAb could be new markers for the early diagnosis of endometriosis.
为了避免症状出现与诊断之间的长时间延迟,迫切需要一种能够进行子宫内膜异位症非侵入性诊断的方法。目前非常需要一种同时具有高灵敏度和特异性的生物标志物。在这里,我们描述了使用蛋白质组学方法来鉴定潜在的新的子宫内膜抗原,方法是使用子宫内膜异位症患者和健康对照者的血清进行 1D 和 2D 印迹western 分析,并评估这些生物标志物在子宫内膜异位症非侵入性诊断中的应用。
进行了一项横断面研究,使用早期子宫内膜异位症(n = 17)、晚期子宫内膜异位症(n = 23)和无子宫内膜异位症(n = 30)患者的 1D 和 2D western 印迹来鉴定特定的子宫内膜抗原。使用基质辅助激光解吸/电离-飞行时间/质谱联用分析(MALDI-TOF/MS)和 MASCOT 分析对 5 个免疫反应性斑点进行了分析。为了验证,我们在包括早期子宫内膜异位症(n = 18)、晚期子宫内膜异位症(n = 32)和无子宫内膜异位症(n = 27)患者的独立队列中建立了针对特定表位的 ELISA,并估计了自身抗体滴度。
2D western blot 分析鉴定出三种子宫内膜抗原,即原肌球蛋白 3(TPM3)、胃动蛋白样蛋白 2(SLP2)和肌动蛋白丝调蛋白 3(TMOD3)。与对照组相比,子宫内膜异位症患者血清中针对 TPM3、SLP2 和 TMOD3 蛋白免疫显性区域表位的抗体水平显著升高。血清抗 TPM3a-自身抗体(61%,93%)、抗 TPM3c-自身抗体(44%,93%)、抗 TPM3d-自身抗体(78%,89%)、抗 SLP2a-自身抗体(50%,96%)、抗 SLP2c-自身抗体(61%,93%)、抗 TMOD3b-自身抗体(61%,96%)、抗 TMOD3c-自身抗体(78%,93%)和抗 TMOD3d-自身抗体(78%,96%)的敏感性和特异性均优于血清 CA125 水平(21%,89%)在检测子宫内膜异位症早期阶段的应用。
血清抗 TPM3a-自身抗体、抗 TPM3c-自身抗体、抗 TPM3d-自身抗体、抗 SLP2a-自身抗体、抗 SLP2c-自身抗体、抗 TMOD3b-自身抗体、抗 TMOD3c-自身抗体和抗 TMOD3d-自身抗体可能成为子宫内膜异位症早期诊断的新标志物。